CoChat
Sign Up
Cited by 380Pulmonary Hypertension Research and TreatmentsVascular Anomalies and TreatmentsGenomics and Rare Diseases

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

Open access
Gräf, Stefan, Haimel, Matthias, Bleda, Marta, Hadinnapola, Charaka, Southgate, Laura, Li, Wei, Hodgson, Joshua, Liu, Bin, Salmon, Richard M., Southwood, Mark, Machado, Rajiv D., Martin, Jennifer M., Treacy, Carmen M., Yates, Katherine, Daugherty, Louise C., Shamardina, Olga, Whitehorn, Deborah, Holden, Simon, Aldred, Micheala, Bogaard, Harm J., Church, Colin, Coghlan, Gerry, Condliffe, Robin, Corris, Paul A., Danesino, Cesare, Eyries, Mélanie, Gall, Henning, Ghio, Stefano, Ghofrani, Hossein-Ardeschir, Gibbs, J. Simon R., Girerd, Barbara, Houweling, Arjan C., Howard, Luke, Humbert, Marc, Kiely, David G., Kovacs, Gabor, MacKenzie Ross, Robert V., Moledina, Shahin, Montani, David, Newnham, Michael, Olschewski, Andrea, Olschewski, Horst, Peacock, Andrew J., Pepke-Zaba, Joanna, Prokopenko, Inga, Rhodes, Christopher J., Scelsi, Laura, Seeger, Werner, Soubrier, Florent, Stein, Dan F., Suntharalingam, Jay, Swietlik, Emilia M., Toshner, Mark R., van Heel, David A., Vonk Noordegraaf, Anton, Waisfisz, Quinten, Wharton, John, Wort, Stephen J., Ouwehand, Willem H., Soranzo, Nicole, Lawrie, Allan, Upton, Paul D., Wilkins, Martin R., Trembath, Richard C., Morrell, Nicholas W.·2018·Nature Communications
DOI 10.1038/s41467-018-03672-4PMC PMC5897357

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious variation within components of the transforming growth factor-β pathway, particularly the bone morphogenetic protein type 2 receptor ( BMPR2 ), underlies most heritable forms of PAH. To identify the missing heritability we perform whole-genome sequencing in 1038 PAH index cases and 6385 PAH-negative control subjects. Case-control analyses reveal significant overrepresentation of rare variants in ATP13A3, AQP1 and SOX17 , and provide independent validation of a critical role for GDF2 in PAH. We demonstrate familial segregation of mutations in SOX17 and AQP1 with PAH. Mutations in GDF2 , encoding a BMPR2 ligand, lead to reduced secretion from transfected cells. In addition, we identify pathogenic mutations in the majority of previously reported PAH genes, and provide evidence for further putative genes. Taken together these findings contribute new insights into the molecular basis of PAH and indicate unexplored pathways for therapeutic intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-03672-4

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagrams illustrating a the composition of the NIHR BioResource—Rare Diseases (NIHR BR-RD) PAH study and b the analysis strategy to identify novel PAH disease genes. a The study comprised 1048 adult cases (aged 16 or over) attending specialist pulmonary hypertension centres from the UK (n = 731), and additional cases from France (n = 142), The Netherlands (n = 45), Germany (n = 82) and Italy (n = 48). b A series of case-control comparisons including and excluding cases with variants in previously reported disease genes were undertaken using complementary filtering strategies
Fig. 1 Flow diagrams illustrating a the composition of the NIHR BioResource—Rare Diseases (NIHR BR-RD) PAH study and b the analysis strategy to identify novel PAH disease genes. a The study comprised 1048 adult cases (aged 16 or over) attending specialist pulmonary hypertension centres from the UK (n = 731), and additional cases from France (n = 142), The Netherlands (n = 45), Germany (n = 82) and Italy (n = 48). b A series of case-control comparisons including and excluding cases with variants in previously reported disease genes were undertaken using complementary filtering strategiesCC BY · PubMed Central
Fig. 2 Analysis of copy number deletions. a Deletions affecting the BMPR2 locus in 23 PAH cases. Genes are indicated in orange and labelled with their respective gene symbol. Deletions are drawn as blue boxes above the genome axis (grey) showing the genomic position on chromosome 2. The grey box highlights the location of BMPR2. b Locus zoom on BMPR2 highlighting the focal deletions affecting one or more exons. c WGS coverage profiles of a selected set of smaller and larger deletions, visualised with the Integrative Genomics Viewer (IGV)57, with deletions highlighted by red bars. d and e Manhattan plots of the genome-wide case-control comparison of large deletions. In d, all subject are considered. In e, subject with larger deletions affecting the BMPR2 locus are excluded. The adjusted P value threshold of 5 × 10−8 for genome-wide significance is indicated by the red line
Fig. 2 Analysis of copy number deletions. a Deletions affecting the BMPR2 locus in 23 PAH cases. Genes are indicated in orange and labelled with their respective gene symbol. Deletions are drawn as blue boxes above the genome axis (grey) showing the genomic position on chromosome 2. The grey box highlights the location of BMPR2. b Locus zoom on BMPR2 highlighting the focal deletions affecting one or more exons. c WGS coverage profiles of a selected set of smaller and larger deletions, visualised with the Integrative Genomics Viewer (IGV)57, with deletions highlighted by red bars. d and e Manhattan plots of the genome-wide case-control comparison of large deletions. In d, all subject are considered. In e, subject with larger deletions affecting the BMPR2 locus are excluded. The adjusted P value threshold of 5 × 10−8 for genome-wide significance is indicated by the red lineCC BY · PubMed Central
Fig. 3 Manhattan plots of the rare variant analyses, having excluded cases carrying rare variants in previously established PAH genes. Filtered variants were grouped per gene. We tested for an excess of variants in PAH cases within genes using Fisher’s exact test. The negative decadic logarithm of unadjusted or adjusted P-values are plotted against the chromosomal location of each gene. a Burden test of rare PTVs. b Burden test of rare deleterious missense variants. c Burden test combining rare PTVs and likely deleterious missense variants. d SKAT-O test of rare PTVs and missense variants
Fig. 3 Manhattan plots of the rare variant analyses, having excluded cases carrying rare variants in previously established PAH genes. Filtered variants were grouped per gene. We tested for an excess of variants in PAH cases within genes using Fisher’s exact test. The negative decadic logarithm of unadjusted or adjusted P-values are plotted against the chromosomal location of each gene. a Burden test of rare PTVs. b Burden test of rare deleterious missense variants. c Burden test combining rare PTVs and likely deleterious missense variants. d SKAT-O test of rare PTVs and missense variantsCC BY · PubMed Central
Fig. 4 Pedigree structures and analysis of familial transmission of variants in AQP1 and SOX17. a Individual II.1 harbours a heterozygous de novo SOX17 c.411 C > G (p.Y137*) PTV resulting in a premature termination codon, which has been transmitted to the affected male (III.1). No unaffected family members carry the variant. No sample was available from subject III.2. b Proband E011942 has inherited a heterozygous AQP1 c.583 C > T (p.R195W) missense variant from her affected father. No sample was available from the affected sister of the proband. The younger healthy uncle of the index case also carries the AQP1 variant. No samples or further clinical information was available for the grandparents, who were not known to have cardiopulmonary disease. c Both the proband E012415 and her father are affected and carry the rare AQP1 c.527 T > A (p.V176E) missense variant. There was no further information available about the siblings of the father. d Subject E010634 has inherited the heterozygous AQP1 c.583 C > T (p.R195W) missense variant from her affected father. No rare variants in previously reported PAH genes were identified in any of theses families. Index cases are highlighted in red. d death, mo months old, yo years old
Fig. 4 Pedigree structures and analysis of familial transmission of variants in AQP1 and SOX17. a Individual II.1 harbours a heterozygous de novo SOX17 c.411 C > G (p.Y137*) PTV resulting in a premature termination codon, which has been transmitted to the affected male (III.1). No unaffected family members carry the variant. No sample was available from subject III.2. b Proband E011942 has inherited a heterozygous AQP1 c.583 C > T (p.R195W) missense variant from her affected father. No sample was available from the affected sister of the proband. The younger healthy uncle of the index case also carries the AQP1 variant. No samples or further clinical information was available for the grandparents, who were not known to have cardiopulmonary disease. c Both the proband E012415 and her father are affected and carry the rare AQP1 c.527 T > A (p.V176E) missense variant. There was no further information available about the siblings of the father. d Subject E010634 has inherited the heterozygous AQP1 c.583 C > T (p.R195W) missense variant from her affected father. No rare variants in previously reported PAH genes were identified in any of theses families. Index cases are highlighted in red. d death, mo months old, yo years oldCC BY · PubMed Central
Fig. 5 Structural analysis of GDF2 mutations. a Schematic diagram of GDF2 processing. The pre-pro-protein is processed into the mature growth factor domain (GFD) bound to the prodomain upon secretion61. b Plot of GDF2 mutations found only in PAH cases superimposed on the structure of prodomain bound GDF2 (PDB: 4YCG)21. The GDF2 growth factor domain is shown in green and the prodomain in cyan. c Magnified view of the Arg110 and Glu143 mutations. The wild-type amino acids make double salt bridges to stabilise the prodomain conformation at the interface between the growth factor domain and prodomain. The E143K and R110W mutations both disrupt these interactions, destabilising the interaction between the growth factor domain and prodomain. d GDF2 levels secreted into supernatants of HEK293T cells transfected with likely pathogenic variants found in PAH cases, compared with wild-type GDF2 and cells transfected with an empty vector. ***P < 0.001 by ANOVA
Fig. 5 Structural analysis of GDF2 mutations. a Schematic diagram of GDF2 processing. The pre-pro-protein is processed into the mature growth factor domain (GFD) bound to the prodomain upon secretion61. b Plot of GDF2 mutations found only in PAH cases superimposed on the structure of prodomain bound GDF2 (PDB: 4YCG)21. The GDF2 growth factor domain is shown in green and the prodomain in cyan. c Magnified view of the Arg110 and Glu143 mutations. The wild-type amino acids make double salt bridges to stabilise the prodomain conformation at the interface between the growth factor domain and prodomain. The E143K and R110W mutations both disrupt these interactions, destabilising the interaction between the growth factor domain and prodomain. d GDF2 levels secreted into supernatants of HEK293T cells transfected with likely pathogenic variants found in PAH cases, compared with wild-type GDF2 and cells transfected with an empty vector. ***P < 0.001 by ANOVACC BY · PubMed Central
Fig. 6 Structural analysis of ATP13A3 mutations. a Topology of ATP13A3, plotted according to UniProtKB Q9H7F0. Frameshift and stop-gained mutations identified in PAH cases are shown as khaki circles, and missense mutations as red circles. Frameshift/stop-gained mutations are predicted to truncate the protein prior to the catalytic domain and essential Mg binding sites, leading to loss of ATPase activity. b Sequence alignment of ATP13A3 with ATP1A1 (P05024), of which the high resolution structure was used for the structural analysis in c. The conserved regions of ATP13A3 and ATP1A1, essential for ATPase activity62, show good alignment (data not shown). Only regions containing the missense PAH mutations are shown, with positions of the four missense mutations highlighted in yellow above the sequences. c Structural analysis of the 4 PAH missense mutations plotted on the ATP1A1 crystal structure based on the sequence alignment in b (PDB: 3wgu)63. Green: α subunit (P05024), cyan: β subunit (P05027), grey: γ-subunit transcript variant a (Q58k79). Y535, Y677, R685 and I787 are the numbering in ATP1A1. Positions of the four missense mutations found in PAH are labelled and highlighted by red circles. d Magnified view of the cytoplasmic region of the ATPase, showing the presence of ADP at the active site. The conserved regions essential for ATPase activity are shown in light pink. The L675V and R858H mutations are located close to the ATP catalytic region
Fig. 6 Structural analysis of ATP13A3 mutations. a Topology of ATP13A3, plotted according to UniProtKB Q9H7F0. Frameshift and stop-gained mutations identified in PAH cases are shown as khaki circles, and missense mutations as red circles. Frameshift/stop-gained mutations are predicted to truncate the protein prior to the catalytic domain and essential Mg binding sites, leading to loss of ATPase activity. b Sequence alignment of ATP13A3 with ATP1A1 (P05024), of which the high resolution structure was used for the structural analysis in c. The conserved regions of ATP13A3 and ATP1A1, essential for ATPase activity62, show good alignment (data not shown). Only regions containing the missense PAH mutations are shown, with positions of the four missense mutations highlighted in yellow above the sequences. c Structural analysis of the 4 PAH missense mutations plotted on the ATP1A1 crystal structure based on the sequence alignment in b (PDB: 3wgu)63. Green: α subunit (P05024), cyan: β subunit (P05027), grey: γ-subunit transcript variant a (Q58k79). Y535, Y677, R685 and I787 are the numbering in ATP1A1. Positions of the four missense mutations found in PAH are labelled and highlighted by red circles. d Magnified view of the cytoplasmic region of the ATPase, showing the presence of ADP at the active site. The conserved regions essential for ATPase activity are shown in light pink. The L675V and R858H mutations are located close to the ATP catalytic regionCC BY · PubMed Central
Fig. 7 Structural analysis of AQP1 mutations. a Multiple sequence alignment of human AQP1 with seven other mammals. The bovine AQP1 has the high resolution (2.2 Å) published structure. Mutations identified in PAH cases are highly conserved and highlighted in yellow. b Crystal structure of bovine AQP1 (PDB: 1j4n)22. Left: side view; right: top view from the extracellular direction. AQP1 is shown as a semi-transparent cartoon and five water molecules in the water channel are shown as red spheres. Key residues lining the water channels are represented with stick structures. c Magnified view of the water channel, with H-bonds connected to water molecules in the channel highlighted. Two asparagine-proline-alanine (NPA) motifs, essential for the water transporting function of AQP1, are shown in magenta. Conserved His180 that constricts the water channel is shown in yellow. Mutations found in PAH cases, Arg195Trp and Val176Glu, are labelled and shown as orange stick structures. Arg195 and His180 are highly conserved in the known water channels and are strong indicators of water channel specificity. Arg195Trp and Val176Glu mutations are predicted to disrupt the conformation of this conserved water channel
Fig. 7 Structural analysis of AQP1 mutations. a Multiple sequence alignment of human AQP1 with seven other mammals. The bovine AQP1 has the high resolution (2.2 Å) published structure. Mutations identified in PAH cases are highly conserved and highlighted in yellow. b Crystal structure of bovine AQP1 (PDB: 1j4n)22. Left: side view; right: top view from the extracellular direction. AQP1 is shown as a semi-transparent cartoon and five water molecules in the water channel are shown as red spheres. Key residues lining the water channels are represented with stick structures. c Magnified view of the water channel, with H-bonds connected to water molecules in the channel highlighted. Two asparagine-proline-alanine (NPA) motifs, essential for the water transporting function of AQP1, are shown in magenta. Conserved His180 that constricts the water channel is shown in yellow. Mutations found in PAH cases, Arg195Trp and Val176Glu, are labelled and shown as orange stick structures. Arg195 and His180 are highly conserved in the known water channels and are strong indicators of water channel specificity. Arg195Trp and Val176Glu mutations are predicted to disrupt the conformation of this conserved water channelCC BY · PubMed Central
Fig. 8 Structural analysis of SOX17 mutations. a Schematic diagram of human SOX17 (Q9H6I2), based on UniProtKB annotation, and published reports23. Red arrows indicate PTVs and black arrows indicate missense mutations identified in PAH patients. The blue bar illustrates the region that is covered in the crystal structure (PDB: 3F27)64. The ability of SOX17 to activate transcription of target genes correlates with binding to β-catenin23. As illustrated, all PTVs lead to a loss of the β-catenin binding region. Two missense mutations are located within and very close to the minimum β-catenin binding regions, and both are highly conserved, indicating they are likely to be important for β-catenin binding. b Structural analysis of HMG domain missense mutations found in PAH patients. Left, Superposition of SOX17/DNA structure (Sox17: cyan, DNA: grey)64 onto SOX2/DNA/Oct1 structure (PDB: 1GT0, Sox2: yellow, Oct1: magenta, DNA: light blue)24. Right: Magnified view of the interactions around Arg140 in the SOX2/DNA/Oct structure. Arg140 in SOX2 makes multiple H-bond interactions and mutating this Arg in SOX2 abolishes the interaction with transcription factors Pax6 and Oct424. SOX2 and SOX17 both bind to Oct465 and SOX17 K122E mutant can replace SOX2 in maintaining stem cell pluripotency65, indicating this region in SOX17 may interact with Oct4, similar to SOX2. The three missense mutations in SOX17 will likely disrupt interaction with Oct4. c Supporting the analysis in b, sequence alignment shows that the HMG domain of SOX2 (P48431) and SOX17 as well as SOX8 (P57073) and SOX18 (P35713) share high sequence identity and the three mutations found in PAH (highlighted in yellow) are highly conserved emphasising their functional importance. Similarly, the Gly and Thr that interact with Arg140 in SOX2 (highlighted in yellow) are also conserved between Oct1 (PO2F1) and Oct4 (PO5F1)
Fig. 8 Structural analysis of SOX17 mutations. a Schematic diagram of human SOX17 (Q9H6I2), based on UniProtKB annotation, and published reports23. Red arrows indicate PTVs and black arrows indicate missense mutations identified in PAH patients. The blue bar illustrates the region that is covered in the crystal structure (PDB: 3F27)64. The ability of SOX17 to activate transcription of target genes correlates with binding to β-catenin23. As illustrated, all PTVs lead to a loss of the β-catenin binding region. Two missense mutations are located within and very close to the minimum β-catenin binding regions, and both are highly conserved, indicating they are likely to be important for β-catenin binding. b Structural analysis of HMG domain missense mutations found in PAH patients. Left, Superposition of SOX17/DNA structure (Sox17: cyan, DNA: grey)64 onto SOX2/DNA/Oct1 structure (PDB: 1GT0, Sox2: yellow, Oct1: magenta, DNA: light blue)24. Right: Magnified view of the interactions around Arg140 in the SOX2/DNA/Oct structure. Arg140 in SOX2 makes multiple H-bond interactions and mutating this Arg in SOX2 abolishes the interaction with transcription factors Pax6 and Oct424. SOX2 and SOX17 both bind to Oct465 and SOX17 K122E mutant can replace SOX2 in maintaining stem cell pluripotency65, indicating this region in SOX17 may interact with Oct4, similar to SOX2. The three missense mutations in SOX17 will likely disrupt interaction with Oct4. c Supporting the analysis in b, sequence alignment shows that the HMG domain of SOX2 (P48431) and SOX17 as well as SOX8 (P57073) and SOX18 (P35713) share high sequence identity and the three mutations found in PAH (highlighted in yellow) are highly conserved emphasising their functional importance. Similarly, the Gly and Thr that interact with Arg140 in SOX2 (highlighted in yellow) are also conserved between Oct1 (PO2F1) and Oct4 (PO5F1)CC BY · PubMed Central
Fig. 9 Immunolocalisation of AQP1, ATP13A3 and SOX17 in normal and PAH lung. The typical histological findings (haematoxylin and eosin staining) of concentric vascular lesions with associated plexiform lesions are shown (a). Higher magnification images of plexiform lesion (b), with frequent endothelialised channels (c; anti-CD31) surrounded by myofibroblasts (d; anti-SMα). Additional high magnification images demonstrating endothelial expression of ATP13A3 (e), AQP1 (f) and SOX17 (g) in PAH lung. Controls lung sections demonstrating predominantly endothelial expression of ATP13A3 (h), AQP1 (i) and SOX17 (j). (Scale bars = 50 µm)
Fig. 9 Immunolocalisation of AQP1, ATP13A3 and SOX17 in normal and PAH lung. The typical histological findings (haematoxylin and eosin staining) of concentric vascular lesions with associated plexiform lesions are shown (a). Higher magnification images of plexiform lesion (b), with frequent endothelialised channels (c; anti-CD31) surrounded by myofibroblasts (d; anti-SMα). Additional high magnification images demonstrating endothelial expression of ATP13A3 (e), AQP1 (f) and SOX17 (g) in PAH lung. Controls lung sections demonstrating predominantly endothelial expression of ATP13A3 (h), AQP1 (i) and SOX17 (j). (Scale bars = 50 µm)CC BY · PubMed Central
Fig. 10 Functional studies of novel genes. a–c Expression of a AQP1, b ATP13A3 and c SOX17 mRNA in human pulmonary artery smooth muscle cells, pulmonary artery endothelial cells and blood outgrowth endothelial cells (BOECs) (n = 4 biological replicates of each). Relative expression of each transcript was normalised to three reference genes, ACTB, B2M and HPRT. d Proliferation of BOECs in 5% FBS over 6 days. Cells were transfected with DharmaFECT1 alone (DH1), siATP13A3 or non-targeting siRNA control (siCP) e, f Quantification of apoptosis in BOECs, defined as Annexin V+/PI− cells, in BOECs transfected with siATP13A3 or siCP in complex with DH1 followed by 24 h treatment with 0.1% FBS or 5% FBS (n = 4 biological repeats). f Measurement of apoptosis via Caspase-Glo 3/7 activity measurements in BOECs transfected with siATP13A3 or siCP in complex with DH1, followed by 16 h treatment in 0.1% FBS or 5% FBS. Data are from a single experiment (n = 4 wells) representative of 3 biological repeats. Data were analysed using a One-way analysis of variance with post hoc Tukey’s test for multiple comparisons in d and f. Data were analysed using a repeated measures One-way analysis of variance with post hoc Tukey’s for multiple comparisons in e. *P < 0.05, **P < 0.01 within treatment groups. ###P < 0.001 for effect of ligand against control for same transfection condition
Fig. 10 Functional studies of novel genes. a–c Expression of a AQP1, b ATP13A3 and c SOX17 mRNA in human pulmonary artery smooth muscle cells, pulmonary artery endothelial cells and blood outgrowth endothelial cells (BOECs) (n = 4 biological replicates of each). Relative expression of each transcript was normalised to three reference genes, ACTB, B2M and HPRT. d Proliferation of BOECs in 5% FBS over 6 days. Cells were transfected with DharmaFECT1 alone (DH1), siATP13A3 or non-targeting siRNA control (siCP) e, f Quantification of apoptosis in BOECs, defined as Annexin V+/PI− cells, in BOECs transfected with siATP13A3 or siCP in complex with DH1 followed by 24 h treatment with 0.1% FBS or 5% FBS (n = 4 biological repeats). f Measurement of apoptosis via Caspase-Glo 3/7 activity measurements in BOECs transfected with siATP13A3 or siCP in complex with DH1, followed by 16 h treatment in 0.1% FBS or 5% FBS. Data are from a single experiment (n = 4 wells) representative of 3 biological repeats. Data were analysed using a One-way analysis of variance with post hoc Tukey’s test for multiple comparisons in d and f. Data were analysed using a repeated measures One-way analysis of variance with post hoc Tukey’s for multiple comparisons in e. *P < 0.05, **P < 0.01 within treatment groups. ###P < 0.001 for effect of ligand against control for same transfection conditionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

Sorted by citations

Items 301–378 of 378

Related

See all

Metadata

Authors
Gräf, S., Haimel, M., Bleda, M., Hadinnapola, C., Southgate, L., Li, W., Hodgson, J., Liu, B., Salmon, R. M., Southwood, M., Machado, R. D., Martin, J. M., Treacy, C. M., Yates, K., Daugherty, L. C., Shamardina, O., Whitehorn, D., Holden, S., Aldred, M., Bogaard, H. J., Church, C., Coghlan, G., Condliffe, R., Corris, P. A., Danesino, C., Eyries, M., Gall, H., Ghio, S., Ghofrani, H.-A., Gibbs, J. S. R., Girerd, B., Houweling, A. C., Howard, L., Humbert, M., Kiely, D. G., Kovacs, G., MacKenzie Ross, R. V., Moledina, S., Montani, D., Newnham, M., Olschewski, A., Olschewski, H., Peacock, A. J., Pepke-Zaba, J., Prokopenko, I., Rhodes, C. J., Scelsi, L., Seeger, W., Soubrier, F., Stein, D. F., Suntharalingam, J., Swietlik, E. M., Toshner, M. R., van Heel, D. A., Vonk Noordegraaf, A., Waisfisz, Q., Wharton, J., Wort, S. J., Ouwehand, W. H., Soranzo, N., Lawrie, A., Upton, P. D., Wilkins, M. R., Trembath, R. C., & Morrell, N. W.
Affiliations
  • University of Cambridge (GB)
  • St George's, University of London (GB)
  • Royal Papworth Hospital (GB)
  • Addenbrooke's Hospital (GB)
  • Cleveland Clinic (US)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Golden Jubilee National Hospital (GB)
  • The Royal Free Hospital (GB)
  • Royal Hallamshire Hospital (GB)
  • Newcastle University (GB)
  • University of Pavia (IT)
  • Inserm (FR)
  • Justus-Liebig-Universität Gießen (DE)
  • Policlinico San Matteo Fondazione (IT)
  • Imperial College London (GB)
  • Université Paris-Sud (FR)
  • Great Ormond Street Hospital (GB)
  • Ludwig Boltzmann Institute for Lung Vascular Research (AT)
  • Medical University of Graz (AT)
  • Royal United Hospital (GB)
  • Royal Brompton Hospital (GB)
  • University of Sheffield (GB)
  • King's College London (GB)
Corresponding author
  • Gräf, Stefan
  • Morrell, Nicholas W.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2018-04-12
Volume
9
Issue
1
Pages
1416-1416
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-018-03672-4
PMC
PMC5897357
OpenAlex
W2797926700
Cited by
380
References
66
Citations by year
2026: 22 · 2025: 36 · 2024: 36 · 2023: 50 · 2022: 55 · 2021: 56 · 2020: 60 · 2019: 36 · 2018: 28
FWCI
33.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • St George's Online Research Archive (St George's University of London) (acceptedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Apollo (cc-by)
Funders
  • Pulmonary Hypertension Association
  • Wellcome Trust (204809/Z/16/Z, 204809, 204809/Z/16)
  • National Institute for Health and Care Research (NF-SI-0514-10086, 204809/Z/16/Z)
  • British Heart Foundation (PG/17/58/33134, RG/13/4/30107, PG/12/54/29734, FS/13/48/30453, RG/08/006/25302, PG/15/39/31519, SP/12/12/29836, PG/17/1/32532, FS/18/52/33808, FS/15/59/31839)
  • University of Cambridge
  • ZonMw
  • Cambridge University Hospitals (BRC 2012-2017, 146281)
  • Nederlandse Federatie van Universitair Medische Centra
  • Dinosaur Trust
  • NIHR BioResource
  • Medical Research Council (MR/K020919/1, 204809/Z/16/Z)
  • St. George's, University of London
  • NIHR Cambridge Biomedical Research Centre
  • National Heart, Lung, and Blood Institute (R01HL098199)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
heritable pulmonary arterial hypertension, missing heritability, TGF-beta signaling, BMPR2, BMP9, SOX17, aquaporin-1, ATP13A3, family segregation, pathogenic variants, whole genome sequencing
MeSH terms
Whole Genome Sequencing, Adenosine Triphosphatases, Adult, Base Sequence, Female, Gene Expression Regulation, Humans, Male, Models, Molecular, Mutation, Prognosis, Signal Transduction, Case-Control Studies, Transforming Growth Factor beta, Genetic Predisposition to Disease, Membrane Transport Proteins, Aquaporin 1, Bone Morphogenetic Protein Receptors, Type II, Growth Differentiation Factors, Growth Differentiation Factor 2, SOXF Transcription Factors, HEK293 Cells, Familial Primary Pulmonary Hypertension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review